Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió acceptadaData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/66170
Targeting striatal metabotropic glutamate receptor type 5 in Parkinson's disease: bridging molecular studies and clinical trials
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Metabotropic glutamate (mGlu) receptors are G protein-coupled receptors expressed primarily on neurons and glial cells modulating the effects of glutamatergic neurotransmission. The pharmacological manipulation of these receptors has been postulated to be valuable in the management of some neurological disorders. Accordingly, the targeting of mGlu5 receptors as a therapeutic approach for Parkinson's disease (PD) has been proposed, especially to manage the adverse symptoms associated to chronic treatment with classical PD drugs. Thus, the specific pharmacological blocking of mGlu5 receptors constitutes one of the most attractive non-dopaminergic-based strategies for PD management in general and for the L-DOPA-induced diskynesia (LID) in particular. Overall, we provide here an update of the current state of the art of these mGlu5 receptor-based approaches that are under clinical study as agents devoted to alleviate PD symptoms.
Matèries (anglès)
Citació
Citació
VALLANO FERRAZ, Antonio, FERNÁNDEZ DUEÑAS, Víctor, GARCÍA NEGREDO, Gloria, QUIJADA MANUITT, M. angeles, SIMÓN, C. p., CUFFÍ I CHÉLIZ, Maria laura, CARBONELL BARDERA, Lourdes, SÁNCHEZ GONZÁLEZ, S., ARNAU DE BOLÓS, Josep m., CIRUELA ALFÉREZ, Francisco. Targeting striatal metabotropic glutamate receptor type 5 in Parkinson's disease: bridging molecular studies and clinical trials. _CNS & Neurological Disorders-Drug Targets_. 2013. Vol. 12, núm. 8, pàgs. 1128-1142. [consulta: 22 de gener de 2026]. ISSN: 1871-5273. [Disponible a: https://hdl.handle.net/2445/66170]